During the presentation of the venture fund,
Alexey Basov, Investment Director at RVC, also noted: "We hope to create a critical mass of products capable to drive our market of medical devices and pharmaceuticals while showing their applicability, scalability and readiness for the new technologies, process digitalization, new sales channels and new role types on the sophisticated market".
In September, the projects will present their developments to industrial partners and investors at the Demo Days in Moscow and Vienna (Austria) during the contemporary art fair viennacontemporary, one of the world's TOP-10 contemporary art events with 118 galleries from 27 countries.
viennacontemporary is a week-long cultural event that attracts the European business elite and reconciles technological and business events with the exhibition of contemporary art.
BioBridge-2019 tracks: Discovery: In-vitro developments — innovative mechanisms of action and biotargets;
Development: Innovative in-vivo drugs — proof-of-concept in pre-clinical studies;
Go2Market: Innovative projects in clinical development — proof-of-concept in clinical studies, Russia and EU market entry;
Digital Drugs: Innovative treatment methods and digital drugs using AI and Big Data.
Partners seeking to extend their portfolios with innovative products are also welcome to participate. Cooperation with participants: Andrey Sizyukhin sa@chemrar.ru Cooperation with partners: Andrey Bogdanov ab@biobridge2019.ru
Information partnership: Elena Surina es@chemrar.ru
For more details on biobridge-2019, please visit www.biobridge2019.ru